Factors contributing to the preference of Korean patients with Crohn's disease when selecting an anti-tumor necrosis factor agent (Choice study)

IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background/Aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. Results: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was 'doctor's presence' (68.3%, 82/120), and ADA was "easy to use" (34.8%, 24/69). Amid various clinicodemographic data, having a > 60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor's presence might be the main contributing factor for this decision.

Original languageEnglish
Pages (from-to)391-398
Number of pages8
JournalGut and Liver
Volume10
Issue number3
DOIs
StatePublished - 2016

Keywords

  • Adalimumab
  • Crohn disease
  • Infliximab
  • Preference

Fingerprint

Dive into the research topics of 'Factors contributing to the preference of Korean patients with Crohn's disease when selecting an anti-tumor necrosis factor agent (Choice study)'. Together they form a unique fingerprint.

Cite this